LinXis Biopharmaceuticals

LinXis has entered a pivotal clinical imaging study to validate its lead Fibrobody® tracer’s ability to target active fibrotic tissue in patients. This will inform patient selection and de-risk subsequent development of their drug-conjugate therapeutics. Preclinical data support selective targeting of activated myofibroblasts across multiple organs. No late-stage efficacy results yet disclosed.[1][2][5][6] The company recently received a TKI–PPP grant to advance its pulmonary fibrosis program.[1] Academic collaboration ongoing with Amsterdam University Medical Center.[6] Historic licensing deal with APO-T B.V. on ADC/linker tech for oncology applications.[8]